Teneobio's Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine Release
(Thomson Reuters ONE) -
MENLO PARK, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Teneobio, Inc, a next-
generation antibody therapeutics company, announced today at the Protein
Engineering Summit (PEGS) in Boston the discovery of a large panel of human
anti-CD3 binders with diverse affinities and tune-able T-cell activation. The
antibodies were generated using TeneoSeek, a proprietary antibody discovery
engine comprising genetically engineered animals, next-generation sequencing and
high throughput vector assembly technologies. Selected anti-CD3 antibodies from
this platform can be incorporated in bi- or multi-specific antibodies for
targeted tumor cell killing, with significantly reduced pro-inflammatory
cytokine release. Such T-cell engaging cancer therapeutics are the next wave of
promising biologics, rivaling CAR-T cell therapy for efficacy, with the added
benefit of off-the-shelf dosing and straightforward manufacturability.
"Bispecifics made from our anti-CD3 leads are differentiated from others in the
clinic in that we can decouple T-cell mediated killing from cytokine release.
We believe that our newly discovered anti-CD3 leads have the potential to retain
tumor cytotoxicity while reducing the incidence of cytokine release syndrome,
providing a greater therapeutic window," said Chief Scientific Officer Wim van
Schooten.
Combination of Teneobio's anti-CD3 antibodies with other fixed light chain or
heavy chain antibodies enables a "plug-and-play" approach to tailor the next
generation of bi- and multi-specific antibodies for T-cell redirection on a
target-specific basis, with reduced toxicity compared to conventional CD3
engaging bispecifics. Teneobio expects to begin clinical development of its
first multi-specific T-cell engager against multiple myeloma in 2018.
Teneobio will partner their anti-CD3 platform through licensing on a non-
exclusive and product-by-product basis.
About Teneobio, Inc.
Teneobio, Inc. is a biotechnology company developing a new class of biologics,
Human Heavy Chain Antibodies (UniAbs(TM)), for the treatments of cancer,
autoimmunity, and infectious diseases. Teneobio's discovery platform, TeneoSeek,
comprises genetically engineered animals (UniRat® and OmniFlic®), next-
generation sequencing, bioinformatics and high-throughput vector assembly
technologies. TeneoSeek rapidly identifies large numbers of unique binding
molecules specific for therapeutic targets of interest. Versatile antibody
variable domains (UniDabs(TM)) derived from UniAbs(TM) can be assembled into
multi-specific and multi-valent therapeutic proteins, surpassing limitations of
conventional antibody therapeutics. Teneobio's "plug-and-play" T cell engaging
platform includes a diverse set of anti-CD3 antibodies for therapeutics with
optimal efficacy and reduced toxicity.
For more information, contact Omid Vafa at ovafa(at)teneobio.com or
visit www.teneobio.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TeneoBio, Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 01.05.2017 - 14:00 Uhr
Sprache: Deutsch
News-ID 539373
Anzahl Zeichen: 3589
contact information:
Town:
Menlo Park
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 208 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Teneobio's Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine Release"
steht unter der journalistisch-redaktionellen Verantwortung von
TeneoBio, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
